No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US OptionsDetailed Quotes
ATAI240719C1500
- 0.10
- 0.000.00%
15min DelayClose Jun 28 15:59 ET
0.50High0.06Low
0.50Open0.10Pre Close22 Volume64 Open Interest1.50Strike Price628.00Turnover130.59%IV20.30%PremiumJul 19, 2024Expiry Date0.00Intrinsic Value100Multiplier19DDays to Expiry0.10Extrinsic Value100Contract SizeAmericanOptions Type0.4070Delta0.9615Gamma13.30Leverage Ratio-0.0041Theta0.0002Rho5.41Eff Leverage0.0012Vega
Intraday
- 5D
- Daily
News
Atai Life Sciences CEO Talks Successful Phase 1 Trial of IV Psilocin Formulation – ICYMI | NASDAQ:ATAI, ETR:9VC
Atai Life Sciences to Participate in the H.C. Wainwright 5th Annual Neuro Perspectives Conference
NEW YORK and BERLIN, June 26, 2024 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ:ATAI) ("atai" or "Company"), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders,
Atai Life Sciences Co-CEO Says Initial Results From ELE-101 Show Promise in Treating Depression | NASDAQ:ATAI, ETR:9VC
Express News | Cantor Fitzgerald Reiterates Overweight on ATAI Life Sciences
Atai Life Sciences Announces Update on Beckley Psytech's Phase 1/2a Trial of ELE-101 (IV Psilocin) for Major Depressive Disorder, With Initial Results From Phase 1 and First Patients Dosed in Phase 2a
ELE-101 is a patent-protected, synthetic formulation of psilocin, designed to offer the therapeutic benefits of psilocybin in a more consistent, controllable, and shorter treatment paradigm of approximately two hours.The
Atai Life Sciences Optimistic as IV Psilocin Shows Promise in Treating Depression in Early Trial | NASDAQ:ATAI, ETR:9VC
Comments
$ATAI Life Sciences(ATAI.US$ atai Life Sciences Announces Update on Beckley Psytech's Phase 1/2a Trial of ELE-101 (IV Psilocin) for Major Depressive Disorder, with Initial Results from Phase 1 and First Patients Dosed in Phase 2a
4 MINUTES AGO, 7:00 AM EDT
VIA GLOBENEWSWIRE
• ELE-101 is a patent-protected, synthetic formulation of psilocin, designed to offer the therapeutic benefits of psilocybin in a more consistent, controllable, and shorter treatment paradigm of approximately two hour...
4 MINUTES AGO, 7:00 AM EDT
VIA GLOBENEWSWIRE
• ELE-101 is a patent-protected, synthetic formulation of psilocin, designed to offer the therapeutic benefits of psilocybin in a more consistent, controllable, and shorter treatment paradigm of approximately two hour...
1
$ATAI Life Sciences(ATAI.US$
atai Life Sciences Announces Update on Beckley Psytech’s Phase 1/2a Trial of ELE-101 (IV Psilocin) for Major Depressive Disorder, with Initial Results from Phase 1 and First Patients Dosed in Phase 2a
atai Life Sciences has provided an update on Beckley Psytech's Phase 1/2a trial of ELE-101 for Major Depressive Disorder (MDD). ELE-101 is a synthetic psilocin formulation designed for a consistent and shorter treatment duration of approximately two hours. The Phas...
atai Life Sciences Announces Update on Beckley Psytech’s Phase 1/2a Trial of ELE-101 (IV Psilocin) for Major Depressive Disorder, with Initial Results from Phase 1 and First Patients Dosed in Phase 2a
atai Life Sciences has provided an update on Beckley Psytech's Phase 1/2a trial of ELE-101 for Major Depressive Disorder (MDD). ELE-101 is a synthetic psilocin formulation designed for a consistent and shorter treatment duration of approximately two hours. The Phas...
2
$ATAI Life Sciences(ATAI.US$ Descending triangle forming on an ancient important key level and positive divergences make us believe in a bullish feeling. The trading volume seems to be significant in these areas, but volume is missing. The Fibonnaci retracement seems to indicate a setback at 1.72, but a possible reversal at $1.42-1.45 could happen to... Anticipation of volatility increase and trading 'Options' suggest that market sentiment is bullish. Will t...
+1
5
$ATAI Life Sciences(ATAI.US$ Atai Life Sciences Disclosed Dosing Of First Patient In Part 2 Of Beckley Psytech's Phase 2a Study Exploring BPL-003 Adjunctive To SSRIs In Patients With Treatment Resistant Depression
1
$ATAI Life Sciences(ATAI.US$ Gap down from 2.63 to 1.50 has finally been completely filled today! Break upward past 2.85? And 3.10 with buy side pressure is next lvl![]()
1
Read more